Status:
UNKNOWN
Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Glaucoma
Corneal Transplantation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glaucoma is the most common threat to vision rehabilitation in patients with Boston keratoprosthesis type 1 (KPro) implantation. High intraocular pressure (IOP) is the most important risk factor for g...
Detailed Description
The only curative treatment for corneal diseases that progress to vision loss is corneal transplantation (CT). Penetrating keratoplasty (PK) involves the surgical replacement of the host cornea with a...
Eligibility Criteria
Inclusion
- Aged 18 years old or older
- Informed consent
- Ability to be followed for the duration of the study
- Presence of ocular disease specified for each group
- Specific criteria for each group:
- Group 1 : have no glaucoma and no systemic diseases
- Group 2 : need to have glaucoma filtration surgery without prior corneal transplantation
- Group 3 : need to have corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis), with or without glaucoma
- Group 4 : need to have intraocular surgery after prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)
- Group 5 : need to have glaucoma filtration surgery with prior corneal transplantation (penetrating keratoplasty or Boston keratoprosthesis)
Exclusion
- Aged less than 18
- Inability to give informed consent
- Presence of ocular diseases other than those studied herein
Key Trial Info
Start Date :
May 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04339907
Start Date
May 11 2020
End Date
May 1 2025
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada, H2X 3E4